UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL. In general:
|
|
- Grant Davidson
- 6 years ago
- Views:
Transcription
1 HCV Retreatment of DAA Failures JORGE L. HERRERA, MD, MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL DAA Drug Classes NS3/4 (protease) inhibitors Telaprevir, boceprevir, simeprevir, paritaprevir Coming soon: grazoprevir NS5a Inhibitors Ledipasvir, dasabuvir, Daclatasvir Coming soon: Elbasvir, velpatasvir NS5b (polymerase) Sofosbuvir (nucleoside) Ombitasvir (non-nucleoside) In general: Resistance is shared among classes New generation drugs may overcome resistance within class Resistant mutants are sensitive to drugs from other classes Basis for multiple drug cocktails Copyright 2015 American College of Gastroenterology 1
2 Barrier to Resistance Drug Class Examples Barrier to Resistance Protease inhibitors Protease inhibitors 2 nd generation NS5a inhibitors Nucleoside NS5b inhibitors Non-nucleoside NS5b Inhibitors Telaprevir, boceprevir, simeprevir, paritaprevir ++ Grazoprevir +++ Ledipasvir, ombitasvir, daclatasvir ++ Sofosbuvir Dasabuvir + + = very low barrier to resistance = very high barrier to resistance Schaefer EA, et al. Gastroenterology 2012;142: Determinants of barrier to resistance Number of mutation needed to become resistant 1 st Generation protease inhibitors Genotype 1a 1 mutation Genotype 1b 2+ mutations Fitness of the resultant mutant Nucleoside polymerase inhibitor resistant mutant very unfit Protease inhibitor resistant mutant retain some fitness Non-nucleoside polymerase inhibitor mutants remain fit NS5a remain fit Copyright 2015 American College of Gastroenterology 2
3 Persistence of Resistance After Failure to Pr/O/D Genotype 1a patients Persistence assessed 48 weeks after discontinuation of therapy Resistance Mutation Percent Persisting at 48 wk NS3 9% NS5b (non-nucleoside) nucleoside) 57% NS5a 96% Informs decision making process on how to re-treat prior failures Krishnan P, et al. J Hepatol 2015;62:S220, Abstract O057 Resistant Variants are Selected During Therapy Resistant Baseline Antiviral Therapy variants expand X X Sensitive (wild) virus Resistant virus Pawlotsky JM. Clin Liv Dis 2003;7:45-66 Copyright 2015 American College of Gastroenterology 3
4 Patients naïve to DAA therapy Do Pre-existing existing RAV s Affect Outcome? DEPENDS ON THERAPY Genotype 1a Q80K and Simeprevir Q80K is a polymorphism that affects sensitivity to simeprevir Only affects genotype 1a Does it affect response to DAA combination therapy with simeprevir? Copyright 2015 American College of Gastroenterology 4
5 Genotype 1a - Cirrhosis Q80K Negatively Impacts SVR in Cirrhosis Treated with Simeprevir-Sofosbuvir Sofosbuvir Kwo P, et al. EASL 2015 Abstract LP14 Lawitz E, et al. EASL 2015, Abstract LP04 AASLD Guidance on Resistance Testing for SIM + SOF Therapy Genotype 1a Infection + compensated cirrhosis Test of Q80K if considering SOF + SIM therapy If Q80K present, consider alternate therapy Q80K testing not necessary for Genotype 1b Patients without cirrhosis Patients in whom other DAA s are considered Copyright 2015 American College of Gastroenterology 5
6 Effect of Pre-existing existing Mutations on Sofosbuvir/Ledipasvir Therapy Efficacy of sofosbuvir/ledipasvir in treatment- experienced subjects (no prior NS5a) Baseline resistance profiles: Protease Inhibitor (NS3/4) resistance polymorphisms 71% had baseline resistant mutants 98% of those achieved an SVR NS5a resistant polymorphisms 14% of subjects had baseline resistance it polymorphisms 89% achieved an SVR Among subjects that relapsed after therapy 23/37 (62%) had resistant polymorphisms Afdhal N, et al. NEJM 2014;370: Aviator Study No Impact of Baseline RAV s in G1a Patients Treated with Pr/O/D With RAV No RAV Copyright 2015 American College of Gastroenterology 6
7 Do we need to do pre- treatment resistance panels? As of today for patients never exposed to NS5a Resistance panel testing is not needed pre-therapy Except for 1a cirrhosis if simeprevir + sofosbuvir therapy is planned Presence of resistant variants associated with acceptable SVR rates What about advanced cirrhosis???? Future Resistance mutation analysis will be needed in NS5aexperienced patients Clinical Management of DAA Failures Copyright 2015 American College of Gastroenterology 7
8 Clinical Practice Scenarios Failed IFN + boceprevir, telaprevir or simeprevir IFN + sofosbuvir + ribavirin Sofosbuvir + ribavirin Sofosbuvir + simeprevir Sofosbuvir + ledipasvir Paritaprevir + ombitasvir + dasabuvir - + Level of Difficulty PEG-IFN +Telaprevir/Boceprevir/Simeprevir Failures 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% Sofosbuvir + Ledipasvir for Prior Treatment Failure 93% 94% 100% 98% 40/43 62/66 58/58 49/50 12 weeks 24 weeks P+R P+R+PI Afdhal N, et al. NEJM 2014;370: Copyright 2015 American College of Gastroenterology 8
9 Grazoprevir (PI) + Elbasvir (NS5a) Ribavirin for Prior PI Failure (NS5a) + 79 patients (34 cirrhosis), prior failure to PEG + Ribavirin + either: Boceprevir Telaprevir Simeprevir 12 week therapy with grazoprevir, elbasvir and ribavirin SVR12 rates: Overall: 96% (76/79) Prior virologic failure: 95.5% 5% (63/66) Baseline NS3 RAVs: 91.2% (31/34) Baseline NS5a RAVs: 75% (6/8) Forns X, et al. J Hepatol 2015;63: Sofosbuvir Regimen Failures (NS5a-free regimens) Management of prior sofosbuvir failures PEG-IFN + Sofosbuvir + ribavirin i i Sofosbuvir + ribavirin Sofosbuvir-resistant mutants (S282T) are very rare Extremely unfit Do not survive Retreated with Sofosbuvir + ledipasvir + ribavirin 12 weeks SVR-12: 98% (44/45)* *The failure patient was a G3 patient that was misclassified Wyles D, et al. Hepatology 2015;61: Copyright 2015 American College of Gastroenterology 9
10 Is Ribavirin Needed in Sofosbuvir Failures? 14 patients, G1, prior failures to 24 weeks of sofosbuvir + ribavirin Re-treatment: Sofosbuvir + ledipasvir 12 weeks SVR-12: 100% Responses included 1 patient with detectable S282T mutation pre-therapy 7 with cirrhosis Osinusi A, et al. Ann Intern Med 2014;161: Telaprevir or Boceprevir + PEG-IFN or Simeprevir + Sofosbuvir Failures AASLD/IDSA Guidance No Cirrhosis Ledipasvir + sofosbuvir 12 weeks Consider ribavirin if a prior failure to sofosbuvir + simeprevir Cirrhosis Ledipasvir + sofosbuvir 24 weeks Consider ribavirin if a prior failure to sofosbuvir + simeprevir Ledipasvir + sofosbuvir + ribavirin 12 weeks Do not use if prior failure to sofosbuvir + simeprevir Copyright 2015 American College of Gastroenterology 10
11 NS5a-Experienced Patients LEDIPASVIR, DACLATASVIR, OMBITASVIR Resistance Analysis of Select NS5A Inhibitors in G1 HCV 1. Cheng G, et al. EASL 2012, Abstract Krishnan P, et al. Antimicrob Agents Chemother 2015;59: Yang G, et al. EASL Abstract NG T, et al. CROI 2014, Abstract 639 Copyright 2015 American College of Gastroenterology 11
12 Persistence of Treatment- Emergent NS5a RAVs Study of patients not achieving SVR after therapy with LDV without SOF NS5a RAVs persisted in majority of patients for 96 weeks Dvory-Sobol H, et al. EASL Abstract O059 Re-treatment of Sofosbuvir/Ledipasvir Failures Failed 8-12 weeks, re-treated with 24 weeks of ledipasvir + sofosbuvir 100% 90% 80% 70% 60% 50% 40% 30% 20% 10% 0% 100% No NS5a RAV's SVR-12 60% 11/11 18/30 NS5a RAV's Present Lawitz E, et al. J Hepatol 2015;62:S192, Abstract O005 Copyright 2015 American College of Gastroenterology 12
13 Re-Treatment of LDV/SOF Failures Effect of Baseline RAVs NS5b variants (S282T) emerged during retreatment in 4/12 patients with virologic failure Lawitz E, et al. EASL 2015, Abstract O005 Re-Treatment of NS5a Containing Regimen Failures Data is very limited Persistence of NS5a resistant polymorphism is likely Particularly if prior treatment was >12 weeks Co-existence of NS3 resistant polymorphisms affects choice of therapy Pre-treatment resistance testing important Copyright 2015 American College of Gastroenterology 13
14 Treatment of Genotype 1 NS5a-Experienced Patients AASLD/IDSA Guidance If mild liver disease Defer treatment until data available Cirrhosis or need for urgent therapy Test for NS3 and NS5a resistance-associated variants (RAVs) RAV Testing Result Retreatment Regimen Duration No NS5a RAVs Ledipasvir/sofosbuvir + ribavirin 24 weeks NS5a but no NS3 RAVs Simeprevir + sofosbuvir + ribavirin 24 weeks NS5a and NS3 RAVs Refer to clinical trial Testing for Resistance is Commercially Available Resistance Panel Quest LabCorp NS NS5a NS5b Currently, testing is only available for genotype 1 Controversies How accurate are these tests? How many mutations are too many? Which mutations do we need to pay attention to? Copyright 2015 American College of Gastroenterology 14
15 Paritaprevir/Ombitasvir/Dasabuvir Failures Few data available Patients who have failed often have resistance to NS3 NS5a NS5b Defer therapy if mild liver disease Test for resistance if therapy needed now Design a sofosbuvir-based regimen Take Home Points 1. Fortunately, the majority of treated patients are cured! 2. Get it right the first time! 3. For the second time around Treatment is easy if failed a 1 st generation PI Options are good if failed sofosbuvir + ribavirin Use pre-treatment RAVs testing for failures to NS5a Non-nucleoside NS5b 4. Refer to the HCV guidance document for latest updates Copyright 2015 American College of Gastroenterology 15
DAA Drug Classes. HCV Retreatment of DAA Failures. In general:
HCV Retreatment of DAA Failures JORGE L. HERRERA M.D., MACG UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE, MOBILE, AL DAA Drug Classes NS3/4 (protease) inhibitors Telaprevir, boceprevir, simeprevir,
More informationHep C: New Therapies and Implications
Hep C: New Therapies and Implications Presented by: Curtis Cooper, MD, FRCPC January 8, 2015 Hep C: New Therapies and Implications Dr. Curtis Cooper trained at the University of Saskatchewan (MD 1994).
More informationDaclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A Trial
Phase 2a Treatment Naïve and Treatment Experienced Daclatasvir + Sofosbuvir +/- Ribavirin in Genotypes 1-3 A1444-040 Trial Sulkowski MS, et al. N Engl J Med. 2014;370:211-21. A1444-040 Trial: Features
More informationNew DAAs - PIs, NS5a Inhibitors, Pol.-Inhibitors (Nucs and Non-Nucs): Promises and Problems
New DAAs - PIs, NS5a Inhibitors, Pol.-Inhibitors (Nucs and Non-Nucs): Promises and Problems Heiner Wedemeyer Hannover Medical School Germany 1 Disclosures Honoraria for consulting or speaking (last 5 years):
More informationEconomic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with
Economic evaluation of Telaprevir (Incivo ) as add-on therapy to pegylated interferon and ribavirin for the treatment of patients infected with Hepatitis C Genotype 1. January 2012 Telaprevir Summary 1.
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Carnegie Health Care Seminar March 2013 Maris Hartmanis, CEO Corporate presentation,
More informationClinical Criteria for Hepatitis C (HCV) Therapy
Clinical Criteria for Hepatitis C (HCV) Therapy Pre-Treatment Evaluation o Must have chronic hepatitis C and HCV genotype and sub-genotype documented; o HCV RNA quantitative within 90 days of application
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Stockholm Corporate Finance / Financial Hearings Life Science / Healthcaredag
More informationSamatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection
Samatasvir (IDX719), a Potent Pan-Genotypic NS5A Inhibitor, for the Treatment of Hepatitis C Virus (HCV) Infection Douglas Mayers, MD December 11, 2013 1 Idenix: Advancing All-Oral, Pan-Genotypic Combination
More informationA collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Q3-2013 Conference Call 21 November 2013 Presenting team Maris Hartmanis,
More informationDutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era
SPECIAL REPORT Dutch guidance for the treatment of chronic hepatitis C virus infection in a new therapeutic era F.A.C. Berden 1, W. Kievit 2, L.C. Baak 3, C.M. Bakker 4, U. Beuers 5, C.A.B. Boucher 6,
More informationRedeye 28 November 2013
A collaborative and agile pharmaceutical company with an R&D focus on infectious diseases and a leading position in hepatitis C Redeye 28 November 2013 Rein Piir, EVP Corporate Affairs & IR Corporate presentation,
More informationJefferies Health Care Seminar New York, June 3, Maris Hartmanis President & CEO
Jefferies Health Care Seminar New York, June 3, 2014 Maris Hartmanis President & CEO 2 Medivir The emerging European pharma company Headquartered and listed in Stockholm, Sweden ~ 140 employees, of which
More informationNS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection
Journal of Infectious Diseases Advance Access published August 7, 2015 MAJOR ARTICLE NS5A Sequence Heterogeneity and Mechanisms of Daclatasvir Resistance in Hepatitis C Virus Genotype 4 Infection Nannan
More informationSide Effect Management of Current Therapy
Side Effect Management of Current Therapy Jorge L. Herrera, MD, FACG University of South Alabama College of Medicine Historical View of Side Effects Severity of Side Effects SVR Rates IFN tiw IFN + Riba
More informationNo. Sponsor Protocol # Protocol Title: Status
Research Specialists of Texas List of Ongoing Studies No. Sponsor Protocol # Protocol Title: Status 1 Abbott M12-114 2 Hoffman-La Roche, Inc. 598-505 3 Bristol Myers S AI444-038 4 Bristol Myers S AI444-052
More informationNovember A research based specialty pharmaceutical company focused on infectious diseases
A research based specialty pharmaceutical company focused on infectious diseases November 2011 Charlotte Edenius EVP Research & Development Bertil Samuelsson Chief Scientific Advisor Rein Piir EVP Corporate
More informationUS Road Show December 2011
A research based specialty pharmaceutical company focused on infectious diseases US Road Show December 2011 Maris Hartmanis, President and CEO Charlotte Edenius, EVP Research & Development Rein Piir, EVP
More informationResearch Article Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
Canadian Gastroenterology and Hepatology Volume 216, Article ID 626271, 7 pages http://dx.doi.org/1.1155/216/626271 Research Article Clinical Trial Risk in Hepatitis C: Endpoint Selection and Drug Action
More informationEfficient hepatitis C virus genotype 1b Core-NS5A recombinants permit
AAC Accepted Manuscript Posted Online 27 March 2017 Antimicrob. Agents Chemother. doi:10.1128/aac.00037-17 Copyright 2017 American Society for Microbiology. All Rights Reserved. 1 2 Pham et al. (Bukh,
More informationBoceprevir for the treatment of genotype 1 chronic hepatitis C
Boceprevir for the treatment of genotype 1 chronic Issued: April 2012 guidance.nice.org.uk/ta NHS Evidence has accredited the process used by the Centre for Health Technology Evaluation at NICE to produce
More informationDescription of Commitment
U.S. Postmarketing s Table: Name of ANDROGEL (testosterone gel) CREON (pancrelipase) CREON (pancrelipase) / 022309 and 021015 20725 20725 125057/0 Description of A randomized, double-blind, placebocontrolled
More informationAllosteric inhibitors of the NS3 protease from the hepatitis C virus with a new action mechanism
Jornada 2-2012: Zaragoza Allosteric inhibitors of the NS3 protease from the hepatitis C virus with a new action mechanism Zaragoza, 6 de junio de 2012 Content 1. The Research Group 2. The Product a) Target
More informationIdenix Pharmaceuticals: Building a Leading Antiviral Franchise. Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Spring 2005
Idenix Pharmaceuticals: Building a Leading Antiviral Franchise Jean-Pierre Sommadossi, Ph.D. Chairman and CEO Spring 2005 Safe Harbor This presentation includes forward-looking statements about Idenix
More informationScottish Medicines Consortium
Scottish Medicines Consortium interferon alfa 2b (Viraferon and Intron A* ) 18 million IU, solution for injection, multidose pen in combination with ribavirin (Rebetol ) capsules 200 mg No. (258/06) Schering
More informationThe Nottingham eprints service makes this work by researchers of the University of Nottingham available open access under the following conditions.
Vercauteren, Koen and Brown, Richard J.P. and Mesalam, Ahmed Atef and Doerrbecker, Juliane and Bhuju, Sabin and Geffers, Robert and Van Den Eede, Naomi and McClure, C. Patrick and Troise, Fulvia and Verhoye,
More informationTreating and Preventing Infectious Disease. November 2011 Nasdaq: INHX
Treating and Preventing Infectious Disease November 2011 Nasdaq: INHX Safe Harbor This presentation contains forward looking statements about Inhibitex and its business, business prospects, strategy and
More informationDevelopment and Validation of Spectrophotometric Method for Assay Determination and In Vitro Dissolution Studies of Sofosbuvir Tablets
Bakht Zaman et al., J.Chem.Soc.Pak., Vol. 39, No. 06, 2017 962 Development and Validation of Spectrophotometric Method for Assay Determination and In Vitro Dissolution Studies of Sofosbuvir Tablets 1 Bakht
More informationHepatitis C virus management: potential impact of nanotechnology
Elberry et al. Virology Journal (2017) 14:88 DOI 10.1186/s12985-017-0753-1 REVIEW Hepatitis C virus management: potential impact of nanotechnology Mostafa H. Elberry 1,2, Noureldien H. E. Darwish 1,3 and
More informationAllele-Specific Real-Time PCR System for Detection of Subpopulations of Genotype 1a and 1b Hepatitis C NS5B Y448H Mutant Viruses in Clinical Samples
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2011, p. 3168 3174 Vol. 49, No. 9 0095-1137/11/$12.00 doi:10.1128/jcm.00274-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Allele-Specific
More informationSovaldi Pegasys Ribavirin
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.01.25 Subject: Sovaldi Pegasys Ribavirin Page: 1 of 6 Last Review Date: March 18, 2016 Sovaldi Pegasys
More informationBiotech lunch - Stockholm. 12 November 2009
Biotech lunch - Stockholm 12 November 2009 Rein Piir, CFO / IR Medivir contact rein.piir@medivir.se www.medivir.com Pipeline Project Indication(s) Partners/- date of Explorati Optimiz agreement Terms Medivir's
More informationINTERMUNE ANNOUNCES TOP-LINE RESULTS OF PHASE 1B TRIAL OF ITMN-191 (R7227) AND PROVIDES PROGRAM UPDATE
Contact: Jim Goff, InterMune, Inc., 415-466-2228, jgoff@intermune.com INTERMUNE ANNOUNCES TOP-LINE RESULTS OF PHASE 1B TRIAL OF ITMN-191 (R7227) AND PROVIDES PROGRAM UPDATE -- Rapid and significant reductions
More informationThe Role of Clinical Pharmacology in HCV Drug Development: Regulatory Experience
The Role of Clinical Pharmacology in HCV Drug Development: Regulatory Experience Islam R. Younis, Ph.D. Team Leader Office of Clinical Pharmacology Center for Drug Evaluation and Research U.S. Food and
More informationAlessandra mangia. The treatment of. hepatitis c EDIZIONI MINERVA MEDICA
Alessandra mangia The treatment of hepatitis c EDIZIONI MINERVA MEDICA ISBN: 978-88-7711-904-9 2017 EDIZIONI MINERVA MEDICA S.p.A. Corso Bramante 83/85 10126 Torino www.minervamedica.it / e-mail: minervamedica@minervamedica.it
More informationChronic hepatitis C virus (HCV) infection is
Impact of a Baseline Polymorphism on the Emergence of Resistance to the Hepatitis C Virus Nonstructural Protein 5A Replication Complex, BMS-790052 Jin-Hua Sun, 1 Donald R. O Boyle II, 1 Yan Zhang, 1 Chunfu
More informationHealth technology Several treatments for patients with chronic hepatitis C (CHC) were examined. The treatments were:
Effectiveness and cost-effectiveness of initial combination therapy with interferon/peginterferon plus ribavirin in patients with chronic hepatitis C in Germany: a health technology assessment commissioned
More informationCase 1:08-cv Document 1 Filed 03/13/2008 Page 1 of 47
Case 1:08-cv-10414 Document 1 Filed 03/13/2008 Page 1 of 47 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS WATERFORD TOWNSHIP POLICE & FIRE) RETIREMENT SYSTEM, Individually and ) On Behalf of All
More informationCase 1:08-cv Document 1 Filed 03/13/2008 Page 1 of 47
Case 1:08-cv-10414 Document 1 Filed 03/13/2008 Page 1 of 47 UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS WATERFORD TOWNSHIP POLICE & FIRE) RETIREMENT SYSTEM, Individually and ) On Behalf of All
More informationSofosbuvir (SOF) is a recently U.S. Food and
Clinical Evidence and Bioinformatics Characterization of Potential Hepatitis C Virus Resistance Pathways for Sofosbuvir Eric F. Donaldson, Patrick R. Harrington, Julian J. O Rear, and Lisa K. Naeger Sofosbuvir
More informationIncreasing access to Hep C treatment October 2016
Increasing access to Hep C treatment October 2016 Swathi Iyengar EMP/PAU 1 Department of Essential Medicines and Health Products Sofosbuvir & Ledipasvir/Sofosbuvir SOF bought in 2011 by Gilead for 11 billion:
More informationBank of America Merrill Lynch Health Care Conference
Bank of America Merrill Lynch Health Care Conference Doug Manion Senior Vice President, Virology, Neuroscience and Japan May 17, 2012 1 Forward-Looking Information During this meeting, we will make statements
More informationZepatier (Elbasvir/Grazoprevir) & Ribavirin Treatment Agreement
Zepatier (Elbasvir/Grazoprevir) & Ribavirin Treatment Agreement Liver Disease & Hepatitis Program Providers: Brian McMahon, MD; Youssef Barbour, MD; Lisa Townshend-Bulson, FNP-C; Annette Hewitt, FNP-C;
More informationA case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan
Zia et al. Infectious Diseases of Poverty (2018) 7:11 DOI 10.1186/s40249-018-0386-7 CASE STUDY A case of a patient infected with a hepatitis C virus genotype 3a multidrug resistant variant in Pakistan
More informationSOFOSBUVIR WORKING PAPER
PATENT SITUATION OF KEY PRODUCTS FOR TREATMENT OF HEPATITIS C SOFOSBUVIR WORKING PAPER Updated and revised version June 2016 World Health Organization 2016 This report was prepared for the WHO Department
More informationHepatitis C virus (HCV) infects more than 170 million persons
In Vitro Antiviral Activity and Preclinical and Clinical Resistance Profile of Miravirsen, a Novel Anti-Hepatitis C Virus Therapeutic Targeting the Human Factor mir-122 Søren Ottosen, a Todd B. Parsley,
More informationAnalysis of Associative Classification for Prediction of HCV Response to Treatment
International Journal of Computer Applications (975 8887) Analysis of Associative Classification for Prediction of HCV Response to Treatment Enas M.F. El Houby Systems & Information Dept., Engineering
More informationAbdelrahman, Tamer. (2015) Quasispecies dynamics and treatment outcome during early hepatitis C infection in a cohort of HIV-infected men. PhD thesis.
Abdelrahman, Tamer. (2015) Quasispecies dynamics and treatment outcome during early hepatitis C infection in a cohort of HIV-infected men. PhD thesis. http://theses.gla.ac.uk/7402/ Copyright and moral
More informationSequencing Analysis of NS3/4A, NS5A, and NS5B from Patients Infected with HCV Genotype
JCM Accepted Manuscript Posted Online 4 May 2016 J. Clin. Microbiol. doi:10.1128/jcm.00238-16 Copyright 2016, American Society for Microbiology. All Rights Reserved. 1 2 Sequencing Analysis of NS3/4A,
More informationCombination therapy with pegylated interferon plus ribavirin
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY 2007;5:124 129 Impact of Ribavirin Dose Reductions in Hepatitis C Virus Genotype 1 Patients Completing Peginterferon Alfa-2a/Ribavirin Treatment K. RAJENDER REDDY,*
More informationExpensive Drugs Are Making Us Sick!
Expensive Drugs Are Making Us Sick! Stacy Borans, MD Founder/Chief Medical Officer Advanced Medical Strategies stacy.borans@mdstrat.com Legal Mumbo Jumbo All Slides are protected by AMS Copyright 2016
More informationReview of the. VOXILAPREVIR PATENT LANDSCAPE: A scoping report
Review of the VOXILAPREVIR PATENT LANDSCAPE: A scoping report March 2017 2017 World Health Organization (Acting as the host organization for the Secretariat of UNITAID) The designations employed and the
More informationCharacterization of the in vitro antiviral activity and the preclinical and clinical resistance profile
AAC Accepts, published online ahead of print on 10 November 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.04220-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 1 2 Characterization
More informationChronic hepatitis C virus (HCV) infection remains a. Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons
GASTROENTEROLOGY 2013;144:59 61 Development of Robust Hepatitis C Virus Genotype 4 Subgenomic Replicons BETTY PENG, 1 MEI YU, 1 SIMIN XU, 1 YU JEN LEE, 1 YANG TIAN, 1 HUILING YANG, 1 KATIE CHAN, 1 HONGMEI
More informationOverview and Application of the HCV Vertical Resistance Analysis Template
PharmaSUG 2017 - Paper SS07 Overview and Application of the HCV Vertical Resistance Analysis Template Yan Xie, Abbvie Inc. ABSTRACT FDA proposed an updated hepatitis C virus (HCV) vertical resistance draft
More informationSuper-resolution light microscopy studies of the organisation and architecture of the hepatitis C virus RNA replication complex
Super-resolution light microscopy studies of the organisation and architecture of the hepatitis C virus RNA replication complex Christopher Paul Bartlett Submitted in accordance with the requirements for
More informationThe Phenotypic Detection of HCV Polymerase Inhibitor Resistant Subpopulations is Dependent on Relative Resistance and Replication Capacity;
The Phenotypic Detection of HCV Polymerase Inhibitor Resistant Subpopulations is Dependent on Relative Resistance and Replication Capacity; IC 95 and Slope Values can Improve Detection 7 th International
More informationPMAC 2017 ACCESS TO MEDICINES: HOW TO FIX THE BROKEN SYSTEM Changing R&D model
mlallemant@dndi.org PMAC 2017 ACCESS TO MEDICINES: HOW TO FIX THE BROKEN SYSTEM Changing R&D model 2016 MSF report: The way it is conducted today, Research and Development (R&D) Do not deliver for diseases
More informationAchillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs
November 1, 2017 Achillion Reports Third Quarter 2017 Financial Results and Provides Update on Clinical Programs Robust balance sheet to support global expansion of ACH-4471 clinical development program
More informationMedivir Corporate Presentation December, A research-based pharmaceutical company focused on infectious diseases and oncology
Medivir Corporate Presentation December, 2015 A research-based pharmaceutical company focused on infectious diseases and oncology 2 Balanced platform of innovation and revenue generation Locations and
More informationReview of HTA outcomes and timelines in Australia, Canada and Europe
Review of HTA outcomes and timelines in Australia, Canada and Europe 0-07 Figure : First HTA recommendations: comparisons across key jurisdictions 0 and 07 Positive Restriction Negative Multiple Australia
More informationPeptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine Protease
GASTROENTEROLOGY 2012;142:654 663 Peptidomimetic Escape Mechanisms Arise via Genetic Diversity in the Ligand-Binding Site of the Hepatitis C Virus NS3/4A Serine Protease CHRISTOPH WELSCH,*,, TETSURO SHIMAKAMI,*
More informationReview of HTA outcomes and timelines in Australia, Canada and Europe
Review of HTA outcomes and timelines in Australia, and Europe - Figure : HTA Decisions: comparisons across key jurisdictions and Positive Restriction Negative Multiple Australia N=6 N= England N= France
More informationAchillion Pharmaceuticals
Achillion Pharmaceuticals Starting the new year on a solid footing Update on data Pharma & biotech Achillion brings in the new year well positioned, with the announcement of encouraging data from two of
More informationOriginal article Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates
Antiviral Therapy 211; 16:75 718 (doi: 1.3851/IMP1825) Original article Development of a chimeric replicon system for phenotypic analysis of NS3 protease sequences from HCV clinical isolates Amy K Sheaffer
More informationIntercontinental journal of pharmaceutical Investigations and Research
Available online at ISSN: 2349-5448 Intercontinental journal of pharmaceutical Investigations and Research ICJPIR Volume 4 Issue 1 Jan Mar- 2017 Research Article A new analytical method development and
More informationHepatitis C virus (HCV) is a positive-strand enveloped RNA
Use of Illumina Deep Sequencing Technology To Differentiate Hepatitis C Virus Variants Masashi Ninomiya, a Yoshiyuki Ueno, a Ryo Funayama, b Takeshi Nagashima, b Yuichiro Nishida, b Yasuteru Kondo, a Jun
More informationSofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial
Research Preliminary Communication Sofosbuvir and Ribavirin for Hepatitis C Genotype 1 in Patients With Unfavorable Treatment Characteristics A Randomized Clinical Trial Anuoluwapo Osinusi, MD, MPH; Eric
More informationPARITAPREVIR/OMBITASVIR/DASABUVIR
PATENT SITUATION OF KEY PRODUCTS FOR TREATMENT OF HEPATITIS C PARITAPREVIR/OMBITASVIR/DASABUVIR WORKING PAPER Revised version June 2016 World Health Organization 2016 This report was prepared for the WHO
More informationClinical Roundtable Monograph
Clinical Roundtable Monograph G a s t r o e n t e r o l o g y & H e p a t o l o g y M a r c h 2 0 0 9 Ribavirin as a Key Factor in the Treatment of Hepatitis C Faculty John G. McHutchison, MD Associate
More informationHepatitis C virus (HCV) is a major global
Characterization of Hepatitis C Virus Intergenotypic Recombinant Strains and Associated Virological Response to Sofosbuvir/Ribavirin Charlotte Hedskog, 1 Brian Doehle, 1 Krishna Chodavarapu, 1 Viktoria
More informationJ.P. Morgan Healthcare Conference BILL CHASE BILL CHASE EXECUTIVE VP, FINANCE & CFO
J.P. Morgan Healthcare Conference BILL CHASE BILL CHASE EXECUTIVE VP, FINANCE & CFO Disclaimer and Forward Looking Statement This presentation and its contents are confidential and may not be reproduced,
More informationDigestive and Liver Disease
Digestive and Liver Disease 43 (2011) 425 430 Contents lists available at ScienceDirect Digestive and Liver Disease journal homepage: www.elsevier.com/locate/dld Review Article Ribavirin for chronic hepatitis
More informationReview of the. VELPATASVIR PATENT LANDSCAPE: A scoping report
Review of the VELPATASVIR PATENT LANDSCAPE: A scoping report March 2017 2017 World Health Organization (Acting as the host organization for the Secretariat of UNITAID) The designations employed and the
More informationComing of Age of Personalized Medicine. Janet Woodcock M.D. Director, CDER, FDA
Coming of Age of Personalized Medicine Janet Woodcock M.D. Director, CDER, FDA Agenda State of Personalized Medicine Current challenges Scientific Policy Logistical Value related Vision for the future
More informationSimultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC DAD
DOI 10.1186/s13065-016-0232-6 RESEARCH ARTICLE Open Access Simultaneous determination of newly developed antiviral agents in pharmaceutical formulations by HPLC DAD Nourah Zoman Al Zoman 1*, Hadir Mohamed
More informationRetreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis q
Journal of Hepatology 51 (2009) 675 681 www.elsevier.com/locate/jhep Retreatment with pegylated interferon plus ribavirin of chronic hepatitis C non-responders to interferon plus ribavirin: A meta-analysis
More informationTitle: Analysis of HCV quasispecies dynamic under selective pressure of combined therapy
Author's response to reviews Title: Analysis of HCV quasispecies dynamic under selective pressure of combined therapy Authors: Ana CG Jardim (caroljardim@gmail.com) Cíntia Bittar (cibittar@gmail.com) Renata
More informationTherapeutic effectiveness of biosimilar standard interferon versus pegylated interferon for chronic hepatitis C genotypes 2 or 3
BRAZ J INFECT DIS. 2012;16(3):232-236 The Brazilian Journal of INFECTIOUS DISEASES www.elsevier.com/locate/bjid Original Article Therapeutic effectiveness of biosimilar standard interferon versus pegylated
More informationProduct Information IBAVYR (ribavirin) tablets 200mg, 400 mg and 600 mg
Product Information IBAVYR (ribavirin) tablets 200mg, 400 mg and 600 mg NAME OF THE MEDICINE Ribavirin Chemical name: 1-β-D-ribofuranosyl-1H-1,2,4-triazole-3-carboxamide CAS registry number: 36791-04-5
More informationAiming for Global. Research-Driven Pharmaceutical Company. Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma Corporation Aiming for Global Research-Driven Pharmaceutical Company Deutsche Securities Inc. Japan Pharmaceutical Conference 2009 September 30, 2009 CONRAD TOKYO Masayuki Mitsuka,
More informationDigestive and Liver Disease
Digestive and Liver Disease 43 (2011) 850 855 Contents lists available at ScienceDirect Digestive and Liver Disease jou rn al h om epage: www.elsevier.com/locate/dld Review article Pharmacological exposure
More information10/07/2018. Liver directed gene therapy. - An overview. DNA/RNA therapies for Wilson s disease. The liver, organ of choice. Highly vascularised
DNA/RNA therapies for Wilson s disease Julien Baruteau - Great Ormond Street Institute of Child Health, University College London, UK Metabolic Medicine, Great Ormond Street Hospital, London, UK PLAN Landscape
More informationDevelopment of a Second Version of the Cobas AmpliPrep/Cobas TaqMan Hepatitis C Virus Quantitative Test with Improved Genotype Inclusivity
JOURNAL OF CLINICAL MICROBIOLOGY, Sept. 2011, p. 3309 3315 Vol. 49, No. 9 0095-1137/11/$12.00 doi:10.1128/jcm.00602-11 Copyright 2011, American Society for Microbiology. All Rights Reserved. Development
More information2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research. Pharmacological Approaches to Address AR
2016 Europe-Nordic-US Symposium New Frontiers in Antibacterial Resistance Research Pharmacological Approaches to Address AR G.L. Drusano, M.D. Professor and Director Institute for Therapeutic Innovation
More informationCan inhibitors of HIV integrase work on HCV polymerase?
[245g] Can inhibitors of HIV integrase work on HCV polymerase? Marino Artico 1, Roberta Costi 1, Roberto Di Santo 1, Maurizio Fermeglia 2, Marco Ferrone 2, Stefano Manfredini 3, Sabrina Pricl 2 1 Department
More informationReceived 22 October 2010/Returned for modification 4 January 2011/Accepted 28 February 2011
JOURNAL OF CLINICAL MICROBIOLOGY, May 2011, p. 1853 1860 Vol. 49, No. 5 0095-1137/11/$12.00 doi:10.1128/jcm.02139-10 Copyright 2011, American Society for Microbiology. All Rights Reserved. The rs8099917
More informationGenome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans
Genome-wide hepatitis C virus amino acid covariance networks can predict response to antiviral therapy in humans Rajeev Aurora,, John E. Tavis, the Virahep-C Study Group J Clin Invest. 2009;119(1):225-236.
More informationFormulation Development of Sofosbuvir Film Coated Tablet
Formulation Development of Sofosbuvir Film Coated Tablet A Project Report to be submitted in the Department of Pharmacy for the Partial Fulfillment of the Degree of Masters of Pharmacy. Submitted By Jobayda
More informationEvaluation of a New-Generation Line-Probe Assay That Detects 5' Untranslated and Core Regions to Genotype and Subtype Hepatitis C Virus
Immunopathology / LIPA 2.0 GENOTYPING OF HCV Evaluation of a New-Generation Line-Probe Assay That Detects 5' Untranslated and Core Regions to Genotype and Subtype Hepatitis C Virus Rohan Nadarajah, MT(ASCP),
More informationAsian Journal of Research in Pharmaceutical Sciences and Biotechnology
Research Article ISSN: 2349 7114 Asian Journal of Research in Pharmaceutical Sciences and Biotechnology Journal home page: www.ajrpsb.com DIFFERENCES BETWEEN HCV NS3/4A PROTEASE FROM GENOTYPES 1-6: SUBSTRATE
More informationSUPPLEMENTARY INFORMATION
Box S1 Data and analysis Sample construction New molecular entities and novel biologics hereafter novel therapeutics approved by the US Food and Drug Administration (FDA) between January 1, 2005 and December
More informationDNDi Update. DNDi Partners Meeting Rio. Best Science for the Most Neglected. April 2016
DNDi Update April 2016 Best Science for the Most Neglected DNDi Partners Meeting Rio Joao Roberto Ripper Innovation & Access for Neglected Populations A dynamic approach towards 2023 Dr Bernard Pécoul,
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationWake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection
Wake Forest Baptist Medical Center Guideline for Use of Ribavirin in the Treatment of Respiratory Syncytial Virus (RSV) Infection General Information Aerosolized ribavirin has been shown in limited clinical
More informationComparison of Daclatasvir Resistance Barrier on NS5A from HCV Genotypes 1-6:
AAC Accepts, published online ahead of print on 16 June 2014 Antimicrob. Agents Chemother. doi:10.1128/aac.02788-14 Copyright 2014, American Society for Microbiology. All Rights Reserved. 1 2 3 Comparison
More informationTechnical Briefing Seminar - Pricing Policies
Technical Briefing Seminar - Pricing Policies Geneva, Switzerland 10 October 2017 Andrew Rintoul Scientist Innovation Access and Use Essential Medicines and Health Products Outline Access to Medicines
More informationSynthesis and Evaluation of New HCV NS3/4A Protease Inhibitors
Synthesis and Evaluation of New HCV NS3/4A Protease Inhibitors A Major Qualifying Project Report: Submitted to the Faculty Of WORCESTER POLYTECHNIC INSTITUTE In partial fulfillment of the requirements
More informationStructure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C
RESEARCH FUND FOR THE CONTROL OF INFECTIOUS DISEASES Structure-based discovery and development of natural products as Type II JAK2 inhibitors for the treatment of hepatitis C EDL Ma *, CH Leung, P Chiu,
More informationGenotype and Subtype Profiling of PSI-7977 as a. Nucleotide Inhibitor of Hepatitis C Virus. Running title: PSI-7977 as a Nucleotide Inhibitor of HCV
AAC Accepts, published online ahead of print on 19 March 2012 Antimicrob. Agents Chemother. doi:10.1128/aac.00054-12 Copyright 2012, American Society for Microbiology. All Rights Reserved. 1 2 3 4 5 6
More information